- Horizon's competitor Selecta announced that SEL-212 failed to beat Krystexxa in a head-to-head trial in refractory gout patients.
- SEL-212 achieved numerically higher response rates against Krystexxa monotherapy, but Krystexxa in combination with methotrexate will likely achieve significantly higher response rates in the MIRROR trial.
- Krystexxa's position in the refractory gout market should not be threatened by SEL-212.
- Horizon remains in a great position to create additional shareholder value with Tepezza, Krystexxa and also through additional M&A.
For further details see:
Horizon Therapeutics: SEL-212 Data Confirms Krystexxa's Likely Dominant Position In Refractory Gout